オプションチェーンは、Amneal Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Amneal Pharmaceuticalsの市場センチメントを評価します。.

Amneal Pharmaceuticals (NASDAQ:AMRX) 株価情報, オプションチェーン

Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals Inc

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacira Pharmaceuticals (PCRX – Research Report), A...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Amneal Pharmaceuticals (AMRX) and NextCure (NXTC)

In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a decision t...

Appeals court sides with Amneal over Teva in inhaler patent fight

In a regulatory filing, Amneal Pharmaceuticals (AMRX) director Gautam Patel disclosed the sale of 62,590 class A common shares of the company on Ja...

Amneal Pharmaceuticals director Patel sells 62,590 class A shares

Amneal expects to meet or top annual guidance

Backs prior FY24 reveue view $2.7B- $2.B, consensus $2.77B…In connection with a presentation to be made at an investor conference on January 15, Am...

Amneal Pharmaceuticals backs prior FY24 EPS view 57c-63c, consensus 61c

The tentative approval for ANDA 218862 was posted to the Drugs@FDA site. Published first on TheFly – the ultimate source for real-time, market-movi...

Amneal receives FDA tentative approval for ANDA for rifaximin

FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan

Amneal Pharmaceuticals (AMRX) announced that the FDA has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which refere...

Amneal gets FDA approval for memantine/donepezil extended-release capsules

Barclays analyst Balaji Prasad maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report) today and set a price target of $10.00. T...

Barclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with a pr...

Piper Sandler Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)

AMRX

NXTC

PCRX

TEVA

Press Releases

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

Amneal to Report Third Quarter 2024 Results on November 8, 2024

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

Amneal Reports Third Quarter 2024 Financial Results

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Amneal to Participate at Upcoming Investor Conferences

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

NTRB

NTRBW

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ANI Pharmaceuticals

Axsome Therapeutics

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences

Indivior

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pacira BioSciences

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Wave Life Sciences Ltd. - Ordinary Shares

Comments

Amneal Pharmaceuticals

Amneal Pharmaceuticals (AMRX) オプション

Amneal Pharmaceuticals (NASDAQ:AMRX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル